Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA von Chandran, Smita S., Ma, Jiaqi, Klatt, Martin G., Dündar, Friederike, Bandlamudi, Chaitanya, Razavi, Pedram, Wen, Hannah Y., Weigelt, Britta, Zumbo, Paul, Fu, Si Ning, Banks, Lauren B., Yi, Fei, Vercher, Enric, Etxeberria, Inaki, Bestman, Watchain D., Da Cruz Paula, Arnaud, Aricescu, Ilinca S., Drilon, Alexander, Betel, Doron, Scheinberg, David A., Baker, Brian M., Klebanoff, Christopher A.

Volltext

Combined RAF and MEK Inhibition to Treat Activated Non-V600 BRAF-Altered Advanced Cancers von Rustgi, Naryan, Maria, Ann, Toumbacaris, Nicolas, Zhao, HuiYong, Kargus, Katherine, Bryant, Morgan, Waksmundzki, Alexandra, Aricescu, Ilinca, Lefkowitz, Robert A, Li, Bob T, Chou, Joanne, Capanu, Marinela, de Stanchina, Elisa, Misale, Sandra, Shia, Jinru, Yaeger, Rona

Volltext

Concurrent SOS1 and MEK suppression inhibits signaling and growth of NF1-null melanoma von Marasco, Michelangelo, Kumar, Dinesh, Seale, Tessa, Borrego, Santiago Garcia, Kaplun, Esther, Aricescu, Ilinca, Cole, Soren, Qeriqi, Besnik, Qiu, Juan, Chen, Xiaoping, Bahr, Amber, Fidele, Deborah, Hofmann, Marco H., Gerlach, Daniel, Savarese, Fabio, Merghoub, Taha, Wolchok, Jedd D., Yao, Zhan, de Stanchina, Elisa, Solit, David, Misale, Sandra, Rosen, Neal

Volltext